Brain and central nervous system (CNS) cancers often do not receive the same spotlight and level of awareness as other forms of the disease. However, decorated Arizona senator and former presidential candidate, John McCain’s recent diagnosis has brought brain tumors back to attention.
In July 2017, Senator John McCain was diagnosed with an aggressive form of brain cancer, glioblastoma. “Glioblastoma can be difficult to treat. Average survival for malignant glioblastoma tends to be about 14 months with treatment,” says Dr. Sanjay Gupta, a practicing neurosurgeon. Senator McCain has continued to undergo cancer therapies and treatments, such as chemotherapy and radiation.
ABTA: Estimated 80,000 New Cases of Primary Brain Tumors This Year
According to the American Brain Tumor Association, an estimated 80,000 new cases of primary brain tumors will be diagnosed this year. Another 17,000 people are estimated to lose their battle with a primary brain or CNS tumor this year.
Medical professionals continue to hope for a more advanced treatment against these aggressive forms of cancer, as chemotherapy and radiation are still the first-line treatment.
“The brain tumor community is very united in our quest for finding better treatments for our patients, and I think the progress will come through clearly planned and orchestrated clinical trials, looking at both approaches, immunotherapies … and appropriate uses of targeted therapies, which will go and attack the genes that drive a particular tumor,” says Dr. Manmeet Ahluwalia, a brain tumor oncologist and director of the brain metastasis program at the Cleveland Clinic in Ohio.
According to GBI Research, global revenues for the cancer vaccine market are forecast to grow from $2.5 billion in 2015 to $7.5 billion in 2022, which represents a compound annual growth rate (CAGR) of 16.93%.
One company that is actively engaged in the development of a glioblastoma brain tumor vaccine is Innovest Global, Inc. (OTC Pink: IVST).
IVST: Signed Letter of Intent to Acquire 20% of StemVax Therapeutics
Innovest Global, Inc. (OTC Pink: IVST) recently announced that it has signed a Letter of Intent to acquire a 20% stake of StemVax, LLC, a biotechnology company that is currently developing a brain cancer vaccine.
The StemVax Glioblast (SVX-GB) cancer vaccine is being designed to help stimulate the restoration of a patient’s immune system and its ability to fight against existing cancer cells in the body.
Dr. Dwain Morris-Irvin is not only the CEO of the new Innovest Biotechnology & Health Sciences Division, but he also the founder and CEO of StemVax, LLC.
“Innovest is uniquely equipped to provide immeasurably important elements to StemVax that kick things off for StemVax and dramatically improve its potential for success. This is true for other technologies we will encounter, as well. The best way I can show future scientists how Innovest can serve their mission, is to lead by example with my own company,” said Dr. Morris-Irvin. “Dan Martin (Innovest Global CEO) and I have been planning the business model for this division since 2017. It’s unique and will serve both technologists and Innovest well.”
There is no doubt that the demand is there for advanced treatments to fight against a wide range of diseases and ailments, such as brain and CNS cancers. As new technological breakthroughs allow medical professionals to conduct more thorough testing and experimentation, medications will continue to be more effective in treating and eliminating ailments once thought to be incurable.
Outside of biotechnology, Innovest Global, Inc. (OTC Pink: IVST) recently announced that its Innovest Energy Group has signed a Letter of Intent to acquire an energy business that is producing annual revenues of $1.2 million. The energy procurement acquisition target will provide the Energy Division with new technologies and synergies.
Once the energy acquisition is completed, Innovest Global, Inc. (OTC Pink: IVST) is estimated to report baseline quarterly revenues of $800,000. The Energy Division alone will have more than 300 commercial and industrial clients and puts Innovest Global, Inc. (OTC Pink: IVST) in perfect position while the company gets started on developing its Biotechnology & Health Sciences Division.
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand five hundred dollars cash and fifty thousand restricted shares for the creation and dissemination of this content.
This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: https://spotlightgrowth.com//disclosures/